

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

lonafarnib (Zokinvy)

Notes:

- Lonafarnib is only available through Eiger One Care Specialty Pharmacy.

Initiation (new start) criteria: Non-formulary **lonafarnib (Zokinvy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a Geneticist or a specialist in progeria
- Patient is at least 1 year of age
- Patient has a body surface area of at least 0.39 m²
- Patient is diagnosed with one of the following:
 - a. Hutchinson-Gilford Progeria Syndrome
 - b. Processing deficient progeroid laminopathies with documentation of either:
 - i. Heterozygous LMNA mutation with progerin-like protein accumulation
 - ii. Homozygous or compound heterozygous ZMPSTE24 mutations
- Patient is not receiving treatment with a medication that is a strong or moderate CYP3A inhibitor or inducer, midazolam, lovastatin, simvastatin, or atorvastatin

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **lonafarnib (Zokinvy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is at least 1 year of age
- Patient is diagnosed with one of the following:
 - a. Hutchinson-Gilford Progeria Syndrome
 - b. Processing deficient progeroid laminopathies with either:
 - i. Heterozygous LMNA mutation with progerin-like protein accumulation
 - ii. Homozygous or compound heterozygous ZMPSTE24 mutations
- Patient is not receiving treatment with a medication that is a strong or moderate CYP3A inhibitor or inducer, midazolam, lovastatin, simvastatin, or atorvastatin

Continued use criteria (12 months after initiation): Non-formulary **lonafarnib (Zokinvy)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a Geneticist or a specialist in progeria
- Patient is not receiving treatment with a medication that is a strong or moderate CYP3A inhibitor or inducer, midazolam, lovastatin, simvastatin, or atorvastatin.

kp.org

Revised: 05/12/22
Effective: 06/02/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest